Everything tagged "growth" across the TickerSpark archives.
KLA delivered record FY2026 revenue and strong earnings, with AI infrastructure and advanced packaging driving the next leg of growth. The stock earns a Buy, but valuation remains the main risk.
Nebius is scaling rapidly as an AI cloud infrastructure provider, with Q2 revenue up 454% year over year and a $3.0B annualized run-rate. The stock still earns a Hold as valuation, heavy capex, and financing needs offset the growth story.
Fabrinet posted 36% fiscal 2026 revenue growth and 39% EPS growth, powered by surging data center demand. The stock looks expensive on trailing earnings, but forward metrics and capacity expansion support a Buy view.
Alphabet is pairing dominant Search advertising with surging Google Cloud growth and a rapidly expanding AI stack. The stock looks attractive, but rising capex and heavy ad dependence keep the risk profile moderate.
Applied Materials posted record Q3 revenue and strong EPS growth as AI-related spending lifted logic, DRAM, HBM, and advanced packaging demand. The stock is a Buy, though valuation remains the main restraint.
Caterpillar is firing on all cylinders, with record quarterly sales, a swelling backlog, and surging power-generation demand tied to data centers. But the stock already prices in a lot of good news, leaving limited room for execution missteps.
Meta’s ad engine is accelerating on AI-driven ranking and conversion gains, but heavy capex and Reality Labs losses keep the story capital-intensive.
CDNL's insider buying is landing alongside 64% organic Q1 growth, a raised 2026 revenue outlook, and record backlog. The stock has cooled, but that reset makes management's conviction more meaningful—not less.
Targa Resources is benefiting from record Permian volumes, expanding NGL infrastructure, and strong export demand. The stock earns a Buy as growth momentum offsets a still-levered balance sheet.
CAAP posted strong 1Q26 growth as revenue, EBITDA, and EPS all rose sharply, supported by higher passenger traffic and better monetization per traveler. The stock still carries meaningful country and geopolitical risk, but improving leverage and cash generation support a Buy view.
ReNew Energy Global is building a credible renewable growth platform in India, but heavy leverage and negative free cash flow keep the stock at Hold. Manufacturing and storage add upside, yet execution risk remains high.
AstraZeneca’s oncology and respiratory franchises are offsetting legacy erosion, supporting a Buy rating despite leverage and trial risk. The stock looks reasonably valued with multiple late-stage catalysts still ahead.
Generate AI research on any ticker — grades, price targets, and full analysis in minutes.
Open the GeneratorCancel anytime